← FDA DRUG APPROVALS

FDA ANDA · ANDA202693

ACETAZOLAMIDE

Sponsor: AVET LIFESCIENCES

APPLICATION
ANDA202693
TYPE
ANDA
ORIGINAL APPROVAL
2014-12-19
LATEST ACTION
2026-06-05
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

ACETAZOLAMIDE SODIUMPrescription
ACETAZOLAMIDE SODIUM EQ 500MG BASE/VIAL · INJECTABLE · INJECTION

Approval history

2026-06-05Labeling · Supplement 12 · standardAP
2024-07-26Labeling · Supplement 7 · standardAP
2024-07-26Labeling · Supplement 5 · standardAP
2014-12-19UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →